Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 147, Issue 6, Pages 1509-1518Publisher
WILEY
DOI: 10.1002/ijc.32889
Keywords
immunotherapy; CD8(+)T cells; myeloid cells; biomarkers of response
Categories
Funding
- Labex Immuno-Oncology
- SIRIC CARPEM
- INCA PL Bio
- INCA PHRC (Predimel)
- Fondation ARC
- Ligue Contre le Cancer
- Foncer
Ask authors/readers for more resources
Immunotherapy has revolutionized the management of cancers. At the end of 2018, 1,716 clinical trials assessed regimen that combine program death-1 (PD-1)/program death ligand-1 (PD-L1) blockers with other cancer therapies (tyrosine kinase inhibitor, chemotherapy and radiotherapy). There is a contrast between these clinical dynamics and the difficulty of identifying biomarkers to better select patients that could benefit from immunotherapy. In this context, different tumor classifications have been proposed to try to better stratify patients. They rely on the characteristics of the tumor microenvironment and led first to divide them into hot and cold tumors. In this review, we aim to demonstrate the limitations of this classification focusing on the differential significance of subpopulations of intratumor CD8 + T cells. We also underline novel mechanisms of resistance to anti-PD-1/PD-L1 blockade, focusing on myeloid cells, hypoxia and tumor immunoediting under treatment. Understanding the mechanisms of resistance to immune-checkpoint inhibitor is indeed a powerful research driver that allows further identification of novel biomarkers, drug development and bring a rational to innovative therapeutic combinations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available